At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Daratumumab Injectiondrug
Likely dose
Daratumumab Injection 1800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Pilot Study of Daratumumab SC in Patients With Mild to Moderate Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Daratumumab Injection for Alzheimer Disease. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsJanssen Scientific Affairs, LLC
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartNov 2019
Primary CompletionJun 2023
Study CompletionAug 2023
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartNov 6, 2019
Primary CompletionJun 8, 2023
Study CompletionAug 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.8 years ago
Interventions
Daratumumab Injectiondrug
Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion